Company · CIK 0001635088 · SIC 2834 — Pharmaceutical Preparations · Nasdaq

Roivant Sciences Ltd. · ROIV

Insider activity reported against this company. All insider holders · Files at: AXON, UROV, MYOV, ABUS. On EDGAR ↗

Period1M 3M 6M 1Y 2Y All datashares as filed — not split-adjusted

Open-market activity at this companybuys $0 · 0sales $248.7M · 14net −$248.7M

Open-market trades as an insider elsewherebuys $95.0M · 4sales $0 · 0net $95.0M

Reported at this company — common stock

Trade	Reported (ET)	Insider	Shares	Avg price	Total	Owned after	Δ stake	Flags
Sep 20, 2026 FForm 4 →	Sep 22, 9:00 pm EDT	Jennifer HumesChief Accounting Officer	3,880	$39.77	$154,308	106,419	—
Sep 20, 2026 FForm 4 →	Sep 22, 6:26 pm EDT	Richard PulikCFO	2,129	$39.77	$84,670	269,681	—
Sep 16, 2026 AForm 4 →	Sep 18, 9:00 pm EDT	Keith S ManchesterDirector	5,054	—	—	1,753,457	—
Sep 16, 2026 AForm 4 →	Sep 18, 7:12 pm EDT	Daniel Allen GoldDirector	5,054	—	—	8,965,815	—
Sep 16, 2026 AForm 4 →	Sep 18, 7:06 pm EDT	Ilan OrenDirector	5,054	—	—	123,680	—
Sep 16, 2026 AForm 4 →	Sep 18, 7:01 pm EDT	James C MomtazeeDirector	5,054	—	—	111,959	—
Sep 16, 2026 AForm 4 →	Sep 18, 6:57 pm EDT	Meghan FitzgeraldDirector	5,054	—	—	41,162	—
Sep 16, 2026 AForm 4 →	Sep 18, 6:56 pm EDT	Melissa B, EpperlyDirector	5,054	—	—	14,954	—
Sep 15, 2026 SForm 4 →	Sep 17, 6:43 pm EDT	Melissa B, EpperlyDirector	4,938	$39.74	$196,230	9,900	−33.3%	10b5-1
Sep 15, 2026 SForm 4 →	Sep 17, 6:42 pm EDT	Meghan FitzgeraldDirector	5,112	$39.74	$203,152	36,108	−12.4%	10b5-1
Sep 10, 2026 FForm 4 →	Sep 14, 9:00 pm EDT	Daniel Allen GoldDirector	5,133	$40.94	$210,145	8,960,761	—
Sep 10, 2026 FForm 4 →	Sep 14, 6:42 pm EDT	Ilan OrenDirector	2,378	$40.94	$97,355	118,626	—
Sep 10, 2026 FForm 4 →	Sep 14, 6:34 pm EDT	Melissa B, EpperlyDirector	2,179	$40.94	$89,208	14,838	—
Sep 10, 2026 FForm 4 →	Sep 14, 6:29 pm EDT	Meghan FitzgeraldDirector	1,743	$40.94	$71,358	41,220	—
Sep 10, 2026 FForm 4 →	Sep 14, 6:25 pm EDT	James C MomtazeeDirector	2,905	$40.94	$118,931	106,905	—
Sep 8, 2026 SForm 4 →	Sep 10, 9:00 pm EDT	Meghan FitzgeraldDirector	20,000	$39.90	$798,000	42,963	−31.8%	10b5-1
Sep 8, 2026 MForm 4 →	Sep 10, 9:00 pm EDT	Meghan FitzgeraldDirector	20,000	$8.80	$176,000	62,963	—	10b5-1
Aug 28, 2026 SForm 4 →	Sep 1, 9:00 pm EDT	Eric VenkerPresident & Immunovant CEO	200,000	$35.77	$7,153,393	1,599,154	−11.1%	10b5-1
Aug 28, 2026 MForm 4 →	Sep 1, 9:00 pm EDT	Eric VenkerPresident & Immunovant CEO	200,000	$3.85	$770,000	1,799,154	—	10b5-1
Aug 20, 2026 FForm 4 →	Aug 24, 9:00 pm EDT	Richard PulikCFO	5,749	$36.84	$211,793	271,810	—
Aug 20, 2026 FForm 4 →	Aug 24, 9:00 pm EDT	Eric VenkerPresident & Immunovant CEO	13,909	$36.84	$512,408	1,599,154	—
Aug 19, 2026 SForm 4 →	Aug 21, 9:00 pm EDT	Mayukh SukhatmePresident & CIO, Director	335,174	$36.88	$12,360,813	18,630,739	−1.77%
Aug 19, 2026 MForm 4 →	Aug 21, 9:00 pm EDT	Mayukh SukhatmePresident & CIO, Director	335,174	$3.85	$1,290,420	18,775,495	—
Aug 14, 2026 SForm 4 →	Aug 18, 9:00 pm EDT	Mayukh SukhatmePresident & CIO, Director	664,826	$36.34	$24,160,402	18,630,739	−3.45%
Aug 14, 2026 MForm 4 →	Aug 18, 9:00 pm EDT	Mayukh SukhatmePresident & CIO, Director	664,826	$3.85	$2,559,580	18,662,540	—
Jul 27, 2026 SForm 4 →	Jul 29, 9:00 pm EDT	Eric VenkerPresident & Immunovant CEO	200,000	$34.95	$6,990,000	1,613,063	−11.0%	10b5-1
Jul 27, 2026 MForm 4 →	Jul 29, 9:00 pm EDT	Eric VenkerPresident & Immunovant CEO	200,000	$3.85	$770,000	1,813,063	—	10b5-1
Jul 17, 2026 AForm 4 →	Jul 21, 9:00 pm EDT	James C MomtazeeDirector	405	—	—	109,810	—
Jul 17, 2026 AForm 4 →	Jul 21, 9:00 pm EDT	Melissa B, EpperlyDirector	543	—	—	17,017	—
Jul 17, 2026 AForm 4 →	Jul 21, 9:00 pm EDT	Ilan OrenDirector	775	—	—	121,004	—
Jun 30, 2026 FForm 4 →	Jul 2, 7:06 pm EDT	Matthew GlineCEO, Director	76,171	$35.39	$2,695,692	16,659,945	—
Jun 30, 2026 SForm 4 →	Jul 2, 7:03 pm EDT	Meghan FitzgeraldDirector	10,000	$34.90	$349,000	42,963	−18.9%	10b5-1
Jun 30, 2026 MForm 4 →	Jul 2, 7:03 pm EDT	Meghan FitzgeraldDirector	10,000	$8.80	$88,000	52,963	—	10b5-1
Jun 30, 2026 FForm 4 →	Jul 2, 7:01 pm EDT	Frank TortiPresident and Vant Chair	40,310	$35.39	$1,426,571	13,536,202	—
Jun 30, 2026 FForm 4 →	Jul 2, 7:00 pm EDT	Mayukh SukhatmePresident & CIO, Director	46,878	$35.39	$1,659,012	18,630,739	—
Jun 29, 2026 SForm 4 →	Jul 1, 6:34 pm EDT	Melissa B, EpperlyDirector	17,750	$34.38	$610,252	16,474	−51.9%	10b5-1
Jun 29, 2026 MForm 4 →	Jul 1, 6:34 pm EDT	Melissa B, EpperlyDirector	17,750	$4.46	$79,165	34,224	—	10b5-1
Jun 26, 2026 SForm 4 →	Jun 30, 8:38 pm EDT	Keith S ManchesterDirector	1,638,163	$34.46	$56,444,076	1,748,403	−48.4%
Jun 26, 2026 SForm 4 →	Jun 30, 8:30 pm EDT	Daniel Allen GoldDirector	1,438,163	$34.32	$49,354,076	13,689,166	−9.51%
Jun 26, 2026 SForm 4 →	Jun 30, 7:59 pm EDT	QVT Financial LPOther	1,438,163	$34.32	$49,354,076	13,689,166	−9.51%
Jun 25, 2026 SForm 4 →	Jun 29, 6:23 pm EDT	Mayukh SukhatmePresident & CIO, Director	1,000,000	$34.11	$34,105,000	18,677,617	−5.08%
Jun 25, 2026 MForm 4 →	Jun 29, 6:23 pm EDT	Mayukh SukhatmePresident & CIO, Director	1,000,000	$3.85	$3,850,000	19,177,617	—
Jun 24, 2026 SForm 4 →	Jun 26, 6:13 pm EDT	Eric VenkerPresident & Immunovant CEO	200,000	$33.16	$6,631,268	1,613,063	−11.0%	10b5-1
Jun 24, 2026 MForm 4 →	Jun 26, 6:13 pm EDT	Eric VenkerPresident & Immunovant CEO	200,000	$3.85	$770,000	1,813,063	—	10b5-1
Jun 20, 2026 FForm 4 →	Jun 23, 9:17 pm EDT	Richard PulikCFO	2,129	$31.43	$66,914	276,420	—
Jun 20, 2026 FForm 4 →	Jun 23, 9:16 pm EDT	Jennifer HumesChief Accounting Officer	3,582	$31.43	$112,582	109,782	—

Reported at this company — derivatives (options, RSUs, warrants)

Trade	Reported (ET)	Insider	Shares	Avg price	Total	Owned after	Δ stake	Flags
Sep 16, 2026 AForm 4 →	Sep 18, 9:00 pm EDT	Keith S ManchesterDirector	10,531	—	—	10,531	—
Sep 16, 2026 AForm 4 →	Sep 18, 7:12 pm EDT	Daniel Allen GoldDirector	10,531	—	—	10,531	—
Sep 16, 2026 AForm 4 →	Sep 18, 7:06 pm EDT	Ilan OrenDirector	10,531	—	—	10,531	—
Sep 16, 2026 AForm 4 →	Sep 18, 7:01 pm EDT	James C MomtazeeDirector	10,531	—	—	10,531	—
Sep 16, 2026 AForm 4 →	Sep 18, 6:57 pm EDT	Meghan FitzgeraldDirector	10,531	—	—	10,531	—
Sep 16, 2026 AForm 4 →	Sep 18, 6:56 pm EDT	Melissa B, EpperlyDirector	10,531	—	—	10,531	—
Sep 8, 2026 MForm 4 →	Sep 10, 9:00 pm EDT	Meghan FitzgeraldDirector	20,000	—	—	18,578	—	10b5-1
Aug 28, 2026 MForm 4 →	Sep 1, 9:00 pm EDT	Eric VenkerPresident & Immunovant CEO	200,000	—	—	3,844,834	—	10b5-1
Aug 19, 2026 MForm 4 →	Aug 21, 9:00 pm EDT	Mayukh SukhatmePresident & CIO, Director	335,174	—	—	13,224,363	—
Aug 14, 2026 MForm 4 →	Aug 18, 9:00 pm EDT	Mayukh SukhatmePresident & CIO, Director	664,826	—	—	13,559,537	—
Jul 27, 2026 MForm 4 →	Jul 29, 9:00 pm EDT	Eric VenkerPresident & Immunovant CEO	200,000	—	—	4,044,834	—	10b5-1
Jun 30, 2026 MForm 4 →	Jul 2, 7:03 pm EDT	Meghan FitzgeraldDirector	10,000	—	—	38,578	—	10b5-1
Jun 29, 2026 MForm 4 →	Jul 1, 6:34 pm EDT	Melissa B, EpperlyDirector	17,750	—	—	169,166	—	10b5-1
Jun 25, 2026 MForm 4 →	Jun 29, 6:23 pm EDT	Mayukh SukhatmePresident & CIO, Director	1,000,000	—	—	14,224,363	—
Jun 24, 2026 MForm 4 →	Jun 26, 6:13 pm EDT	Eric VenkerPresident & Immunovant CEO	200,000	—	—	4,244,834	—	10b5-1

Filed by this entity as an insider elsewhere — common stock

Trade	Reported (ET)	Company	Shares	Avg price	Total	Owned after	Δ stake	Flags
Dec 18, 2018 PForm 4 →	Dec 20, 6:02 am EST	Axovant Sciences Ltd.AXON	10,000,000	$1.00	$10,000,000	99,285,714	+11.2%	plan?
Oct 1, 2018 PForm 4 →	Oct 3, 4:48 pm EDT	Urovant Sciences Ltd.UROV	2,678,571	$14.00	$37,499,994	22,703,669	+13.4%	plan?
Jun 5, 2018 PForm 4 →	Jun 7, 7:31 am EDT	Axovant Sciences Ltd.AXON	14,285,714	$1.75	$25,000,000	89,285,714	+19.0%	plan?
Apr 2, 2018 PForm 4 →	Apr 4, 4:52 pm EDT	Myovant Sciences Ltd.MYOV	1,110,015	$20.27	$22,500,004	38,341,357	+2.98%	plan?

Filed by this entity as an insider elsewhere — derivatives (options, RSUs, warrants)

Trade	Reported (ET)	Company	Shares	Avg price	Total	Owned after	Δ stake	Flags
Jan 12, 2018 PForm 4 →	Jan 16, 6:10 am EST	Arbutus Biopharma CorpABUS	664,000	$100.00	$66,400,000	1,164,000	—
Oct 16, 2017 PForm 4 →	Oct 17, 6:31 am EDT	Arbutus Biopharma CorpABUS	500,000	$100.00	$50,000,000	500,000	—